We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED
GMED 68.95-4.6%4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brian Fukuba who wrote (41)11/11/1997 6:25:00 PM
From: Roger A.  Read Replies (1) of 63
Does anyone know how the Gene Switch technology is panning out? Will it be used initially for inducible transcription in research studies, or is it being pursued to incorporate into human therapy plasmids.

I know a little about Gene Medicine, but feel that real commercialization of nonviral type gene delivery systems is years away. That's why I'm hoping that cash can be generated somewhere else.

It also seems surprising that Gene Medicine was awarded a broad patent for lipid-based gene delivery methods seeing that Vical pretty much pioneered it under the direction of Philip Felgner. I'm pretty happy that GMED did that. I guess we'll just have to wait and see when GMED gets to be one of the "hot" biotech stocks.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext